concerti Ausgabe Südwest Januar 2020 by concerti - Das Konzert- und Opernmagazin - Issuu
Erinnerungen 1848-1914 ..
SI_2011_04 by Schweizer Illustrierte - Issuu
Das Original - S&D-Verlag GmbH
PDF) NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis
HANSEstyle 4 | 2018
Migros-Magazin-20-2021-d-OS by Migros-Genossenschafts-Bund - Issuu
Calaméo - GOUT.CH 2020 DE
PDF) NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis
Weekend Magazin Vorarlberg 2016 KW 42 by Weekend Magazin Vorarlberg - Issuu
Gesamtkatalog_Winkler_Blätterkatalog
AAP Volltextsuche
Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial - Vermersch - -
PDF) Abstracts of the 113th Annual Meeting of the Swiss Neurological Society, Congress Centre Kursaal Interlaken, Interlaken, Switzerland, 18–19 November 2021
PEOPLE - HERZOG & DE MEURON
Discover Germany, Issue 80, November 2019 by Scan Client Publishing - Issuu
Long-term prognostic value of longitudinal measurements of blood neurofilament levels | Neurology Neuroimmunology & Neuroinflammation
PDF) NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis
PDF) Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland
Hamadrich Koscherliste als pdf
europäisches medienkunst festival european media art ... - EMAF
Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial - Vermersch - -
Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial - Vermersch - -
Bödeli Info April by WEBER VERLAG - Issuu
Berliner Künstlerprogramm - Jahrbuch 2020
